Cours Invictus MD Strategies Corp Toronto S.E.
Actions
GENE
CA46183X2086
Produits pharmaceutiques
Cours en clôture
Autres places de cotation
|
||
- CAD | - |
CA 2018 | 2,36 3,22 2,13 | CA 2019 | 4,69 6,4 4,23 | Capitalisation | 104 M 141 M 93,29 M |
---|---|---|---|---|---|
Résultat net 2018 | -19 M -25,91 M -17,12 M | Résultat net 2019 | -35 M -47,72 M -31,54 M | VE / CA 2018 | 45 833 024 x |
Trésorerie nette 2018 | 37,59 M 51,26 M 33,88 M | Dette nette 2019 | 3,85 M 5,24 M 3,47 M | VE / CA 2019 | 22 877 117 x |
PER 2018 |
-5,87
x | PER 2019 |
-2,45
x | Employés | - |
Rendement 2018 * |
-
| Rendement 2019 |
-
| Flottant | 6,83% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Imran Haider
CEO | Chief Executive Officer | - | - |
Trevor Dixon
BRD | Director/Board Member | - | 09/05/19 |
Larry Heinzlmeir
IRO | Public Communications Contact | - | 24/01/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Trevor Dixon
BRD | Director/Board Member | - | 09/05/19 |
Jagdeep Gupta
BRD | Director/Board Member | - | 22/02/22 |
Greg Macdonald
BRD | Director/Board Member | - | 26/01/21 |
Varia. 1 janv. | Capi. | |
---|---|---|
+23,84% | 5,56 Md | |
-33,64% | 3,55 Md | |
-5,20% | 3,01 Md | |
-25,56% | 2,64 Md | |
-10,76% | 2,3 Md | |
+42,02% | 1,95 Md | |
+43,15% | 1,52 Md | |
-12,72% | 1,45 Md | |
+41,90% | 1,38 Md |
- Bourse
- Actions
- Action IVITF
- Action GENE